Skip to content

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Community-acquired Pneumonia, Influenza, COVID-19

REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia.

The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of patients admitted to intensive care with community-acquired pneumonia.

In addition, REMAP-CAP provides and adaptive research platform for evaluation of multiple treatment modalities in the event of a respiratory pandemic such as COVID-19.

REMAP-COVID is a sub-platform of REMAP-CAP that evaluates treatments specific to COVID-19 in the United States of America.

null

Conditions de participation

  • Sexe:

    ALL

  • Âges admissibles:

    18 and up

Critères de participation

REMAP-CAP PLATFORM INCLUSION CRITERIA:

1. Adult patient admitted to an ICU for severe CAP within 48 hours of hospital admission with:

1. symptoms or signs or both that are consistent with lower respiratory tract infection AND
2. Radiological evidence of new onset consolidation (in patients with pre-existing radiological changes, evidence of new infiltrate)
2. Up to 48 hours after ICU admission, receiving organ support with one or more of:

1. Non-invasive or Invasive ventilatory support;
2. Receiving infusion of vasopressor or inotropes or both

PLATFORM EXCLUSION CRITERIA:

1. Healthcare-associated pneumonia:

1. Prior to this illness, is known to have been an inpatient in any healthcare facility within the last 30 days
2. Resident of a nursing home or long term care facility
2. Death is deemed to be imminent and inevitable during the next 24 hours AND one or more of the patient, substitute decision maker or attending physician are not committed to full active treatment
3. Previous participation in this REMAP within the last 90 days

REMAP-COVID PLATFORM INCLUSION CRITERIA

1. Adult patients (≥ 18 years) admitted to hospital with acute illness due to suspected or proven pandemic infection.

REMAP-COVID PLATFORM EXCLUSION CRITERIA

1. Death is deemed to be imminent and inevitable during the next 24 hours AND one or more of the patient, substitute decision maker or attending physician are not committed to full active treatment
2. Patient is expected to be discharged from hospital today or tomorrow
3. More than 14 days have elapsed while admitted to hospital with symptoms of an acute illness due to suspected or proven pandemic infection.
4. Previous participation in this REMAP within the last 90 days

DOMAIN-SPECIFIC ELIGIBLE CRITERIA:

Each domain may have additional eligibility criteria. Refer to the study website for more information (www.remapcap.org).

Lieu de l'étude

South Health Campus
South Health Campus
Calgary, Alberta
Canada

Contactez l'équipe d'étude

St Boniface General Hospital
St Boniface General Hospital
Winnipeg, Manitoba
Canada

Contactez l'équipe d'étude

Primary Contact

Ryan Zarychanski, MD

The Moncton Hospital
The Moncton Hospital
Fredericton, New Brunswick
Canada

Contactez l'équipe d'étude

Primary Contact

Daniel Smyth, MD

Hamilton general Hospital
Hamilton general Hospital
Hamilton, Ontario
Canada

Contactez l'équipe d'étude

Primary Contact

Alison Fox-Robichaud, MD

Grand River Hospital
Grand River Hospital
Kitchener, Ontario
Canada

Contactez l'équipe d'étude

Primary Contact

Theresa Liu, MD

Thunder Bay General Hospital
Thunder Bay General Hospital
Thunder Bay, Ontario
Canada

Contactez l'équipe d'étude

Toronto General Hospital
Toronto General Hospital
Toronto, Ontario
Canada

Contactez l'équipe d'étude

Primary Contact

Lorenzo del Sorbo, MD

Hospital Maisonneuve-Rosemont
Hospital Maisonneuve-Rosemont
Montréal, Quebec
Canada

Contactez l'équipe d'étude

Hopital du Sacre-Coeur de Montreal
Hopital du Sacre-Coeur de Montreal
Montréal, Quebec
Canada

Contactez l'équipe d'étude

Primary Contact

Martin Albert, MD

Regina General Hospital
Regina General Hospital
Saskatoon, Saskatchewan
Canada

Contactez l'équipe d'étude

Primary Contact

Eric Sy, MD

Rockyview General Hospital
Rockyview General Hospital
Calgary, Alberta
Canada

Contactez l'équipe d'étude

Surrey Memorial Hospital
Surrey Memorial Hospital
Surrey, British Columbia
Canada

Contactez l'équipe d'étude

Primary Contact

Anish Mitra, MD

Dr. Everett Chalmers Regional Hospital
Dr. Everett Chalmers Regional Hospital
Fredericton, New Brunswick
Canada

Contactez l'équipe d'étude

Primary Contact

Zeeshan Aslam, MD

Brantford General Hospital
Brantford General Hospital
Brantford, Ontario
Canada

Contactez l'équipe d'étude

Primary Contact

Brenda Reeve, MD

Kingston Health Sciences Centre
Kingston Health Sciences Centre
Kingston, Ontario
Canada

Contactez l'équipe d'étude

Niagara Health
Niagara Health
Saint Catharines, Ontario
Canada

Contactez l'équipe d'étude

Primary Contact

Jennifer Tsang, MD

Mount Sinai Hospital
Mount Sinai Hospital
Toronto, Ontario
Canada

Contactez l'équipe d'étude

Primary Contact

Sangeeta Mehta, MD

McGill University Health Centre
McGill University Health Centre
Montréal, Quebec
Canada

Contactez l'équipe d'étude

Primary Contact

Kosar Khwaja, MD

CIUSS Chaudieres-Appalaches (Levis)
CIUSS Chaudieres-Appalaches (Levis)
Lévis, Quebec
Canada

Contactez l'équipe d'étude

Primary Contact

Patrick Archambault, MD

Centre Hospitalier de l'Université de Sherbrooke
Centre Hospitalier de l'Université de Sherbrooke
Sherbrooke, Quebec
Canada

Contactez l'équipe d'étude

Primary Contact

Francois Lamontagne, MD

Foothills Medical Centre
Foothills Medical Centre
Calgary, Alberta
Canada

Contactez l'équipe d'étude

Royal Alexandra Hospital, Alberta
Royal Alexandra Hospital, Alberta
Edmonton, Alberta
Canada

Contactez l'équipe d'étude

Primary Contact

Demetrios Kutsogiannis, MD

Health Sciences Centre Winnipeg
Health Sciences Centre Winnipeg
Winnipeg, Manitoba
Canada

Contactez l'équipe d'étude

Primary Contact

Ryan Zarychanski, MD

The Saint John General Hospital
The Saint John General Hospital
Fredericton, New Brunswick
Canada

Contactez l'équipe d'étude

Primary Contact

Stephen Robinson, MD

Juravinski Hospital
Juravinski Hospital
Hamilton, Ontario
Canada

Contactez l'équipe d'étude

Primary Contact

Bram Rochwerg, MD

St Mary's General Hospital
St Mary's General Hospital
Kitchener, Ontario
Canada

Contactez l'équipe d'étude

Primary Contact

Rebecca Kruisselbrink, MD

Sunnybrook Health Sciences Centre
Sunnybrook Health Sciences Centre
Toronto, Ontario
Canada

Contactez l'équipe d'étude

Primary Contact

Rob Fowler, MD

Toronto Western Hospital
Toronto Western Hospital
Toronto, Ontario
Canada

Contactez l'équipe d'étude

Primary Contact

Elizabeth Wilcox, MD

Hôpital Fleury
Hôpital Fleury
Montréal, Quebec
Canada

Contactez l'équipe d'étude

Primary Contact

Thomas Hemmerling, MD

CHU de Québec - Université Laval
CHU de Québec - Université Laval
Québec, Quebec
Canada

Contactez l'équipe d'étude

Primary Contact

Alexis Turgeon, MD

Peter Lougheed Centre
Peter Lougheed Centre
Calgary, Alberta
Canada

Contactez l'équipe d'étude

University of Alberta Hospital
University of Alberta Hospital
Edmonton, Alberta
Canada

Contactez l'équipe d'étude

Primary Contact

Wendy Sligl, MD

Grace Hospital
Grace Hospital
Winnipeg, Manitoba
Canada

Contactez l'équipe d'étude

Primary Contact

Gloria Vazquez-Grande, MD

William Osler Health System
William Osler Health System
Brampton, Ontario
Canada

Contactez l'équipe d'étude

Primary Contact

Alexandra Binnie, MD

St. Joseph's Healthcare Hamilton
St. Joseph's Healthcare Hamilton
Hamilton, Ontario
Canada

Contactez l'équipe d'étude

Primary Contact

Deborah Cook, MD

The Ottawa Hospital
The Ottawa Hospital
Ottawa, Ontario
Canada

Contactez l'équipe d'étude

Primary Contact

Lauralyn McIntyre, MD

St. Michael's Hospital Unity Health Toronto
St. Michael's Hospital Unity Health Toronto
Toronto, Ontario
Canada

Contactez l'équipe d'étude

Primary Contact

John Marshall, MD

St Joseph's Health Centre
St Joseph's Health Centre
Toronto, Ontario
Canada

Contactez l'équipe d'étude

Centre Hospitalier de l'Universite de Montreal
Centre Hospitalier de l'Universite de Montreal
Montréal, Quebec
Canada

Contactez l'équipe d'étude

Primary Contact

Michael Chasse, MD

IUCPQ-UL
IUCPQ-UL
Québec, Quebec
Canada

Contactez l'équipe d'étude

Primary Contact

Francois Lellouche, MD

Étude parrainée par
UMC Utrecht
Participants recherchés
Plus d'informations
ID de l'étude: NCT02735707